Efimosfermin

Phase 2Protein / enzyme

Efimosfermin is one of 3 small molecule programs targeting Metabolic Dysfunction-associated Steatohepatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metabolic Dysfunction-Associated SteatohepatitisRecruiting

Metabolic Dysfunction-Associated SteatohepatitisPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Metabolic Dysfunction-Associated Steatohepatitis

#DrugCompanyPhaseTrials

ECC4703

EEccogene

Phase 2

2 2

Mazdutide

Eli Lilly

Preclinical

1 3

Efimosfermin

BBoston Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Metabolic Dysfunction-Associated Steatohepatitis

NCT06920043

Clinical

Trials by Indication[1]

Non-alcoholic Steatohepatitis (NASH)1 trial

A Phase 2a, Randomized, Blinded, Placebo-controlled Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With a Single Arm Open-label Extension

Completed·BBoston Pharmaceuticals·Phase 2·NCT04880031·231 enrolled

Metabolic Dysfunction-associated Steatohepatitis1 trial

A Phase 2, Randomized, Double-blinded, Placebo-controlled Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

Recruiting·BBoston Pharmaceuticals·Phase 2·NCT06920043·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Efimosfermin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Efimosfermin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Efimosfermin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boston Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 2[1]
Company: BBoston Pharmaceuticals

Efimosfermin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Non-alcoholic Steatohepatitis (NASH)1 trial

Metabolic Dysfunction-associated Steatohepatitis1 trial

References

Drug Info

Quick Facts

Related News